{"created":"2023-05-15T14:37:47.803900+00:00","id":48765,"links":{},"metadata":{"_buckets":{"deposit":"86613d55-2d61-4bc6-be48-03be082e8561"},"_deposit":{"created_by":1,"id":"48765","owners":[1],"pid":{"revision_id":0,"type":"depid","value":"48765"},"status":"published"},"_oai":{"id":"oai:repo.qst.go.jp:00048765","sets":["1"]},"author_link":["490949","490946","490947","490955","490951","490958","490948","490956","490945","490957","490952","490954","490950","490953"],"item_8_biblio_info_7":{"attribute_name":"書誌情報","attribute_value_mlt":[{"bibliographicIssueDates":{"bibliographicIssueDate":"2018-03","bibliographicIssueDateType":"Issued"},"bibliographicIssueNumber":"5","bibliographicPageEnd":"764","bibliographicPageStart":"761","bibliographicVolumeNumber":"58","bibliographic_titles":[{"bibliographic_title":"Journal of Radiation Research"}]}]},"item_8_description_5":{"attribute_name":"抄録","attribute_value_mlt":[{"subitem_description":"Carbon-ion radiation therapy (CIRT) for advanced non–small-cell lung cancer (NSCLC) has not been well\nstudied to date. This paper aimed to analyze a retrospective multicenter survey for detecting problems with the\nuse of CIRT for Stage II and III NSCLC (7th UICC TNM Staging System). Inclusion was restricted to patients\nwith Stage II and III NSCLC who received CIRT from November 2003 to December 2014. We gathered the\ndata from three CIRT operating centers on July 2015. Patients with radiotherapy history, patients with cancers\nother than lung cancer, and those receiving palliative therapies were excluded. The patient characteristics, prescribed\ndose/fraction, survival rates, and adverse effects were analyzed. The total number of patients was 64\n(male: 49, female: 15). Of these, 53 patients were medically inoperable. The median age was 76 years (range\n46–91), and the median follow-up period was 18.5 months (range 3.2–121.5). The clinical staging consisted of\n10 Stage IIA, 30 Stage IIB, 23 Stage IIIA and 1 Stage IIIB. The median prescribed dose was 72.0 Gy (RBE)\n(range 52.8–72.0) in 16 fractions (range 4–16). The 2-year overall survival, progression-free survival, and local control\nrates were 62.2% [confidence interval (CI): 47.5–76.9], 42.3% (CI: 28.8–55.8) and 81.8% (CI: 69.9–94.0),\nrespectively. There were no higher than Grade 2 adverse effects observed. CIRT for inoperable Stage II and III\nNSCLC could be implemented without severe adverse effects, but the clinical staging (including lymph node status)\nwas inhomogeneous. In addition, the prescribed dose and fractionation were not standardized. Further data accumulation\nand a multiple centers prospective trial for evaluating clinical stage–based results are required.","subitem_description_type":"Abstract"}]},"item_8_publisher_8":{"attribute_name":"出版者","attribute_value_mlt":[{"subitem_publisher":"Oxford University Press"}]},"item_8_relation_13":{"attribute_name":"PubMed番号","attribute_value_mlt":[{"subitem_relation_type_id":{"subitem_relation_type_id_text":"28992088","subitem_relation_type_select":"PMID"}}]},"item_8_relation_14":{"attribute_name":"DOI","attribute_value_mlt":[{"subitem_relation_type_id":{"subitem_relation_type_id_text":"10.1093/jrr/rrx037","subitem_relation_type_select":"DOI"}}]},"item_8_relation_17":{"attribute_name":"関連サイト","attribute_value_mlt":[{"subitem_relation_name":[{"subitem_relation_name_text":"https://academic.oup.com/jrr/article/58/5/761/3964684"}],"subitem_relation_type_id":{"subitem_relation_type_id_text":"https://academic.oup.com/jrr/article/58/5/761/3964684","subitem_relation_type_select":"URI"}}]},"item_8_source_id_9":{"attribute_name":"ISSN","attribute_value_mlt":[{"subitem_source_identifier":"0449-3060","subitem_source_identifier_type":"ISSN"}]},"item_access_right":{"attribute_name":"アクセス権","attribute_value_mlt":[{"subitem_access_right":"metadata only access","subitem_access_right_uri":"http://purl.org/coar/access_right/c_14cb"}]},"item_creator":{"attribute_name":"著者","attribute_type":"creator","attribute_value_mlt":[{"creatorNames":[{"creatorName":"Karube, Masataka"}],"nameIdentifiers":[{"nameIdentifier":"490945","nameIdentifierScheme":"WEKO"}]},{"creatorNames":[{"creatorName":"Yamamoto, Naoyoshi"}],"nameIdentifiers":[{"nameIdentifier":"490946","nameIdentifierScheme":"WEKO"}]},{"creatorNames":[{"creatorName":"Shioyama, Yoshiyuki"}],"nameIdentifiers":[{"nameIdentifier":"490947","nameIdentifierScheme":"WEKO"}]},{"creatorNames":[{"creatorName":"Saito, Junichi"}],"nameIdentifiers":[{"nameIdentifier":"490948","nameIdentifierScheme":"WEKO"}]},{"creatorNames":[{"creatorName":"Matsunobu, Akira"}],"nameIdentifiers":[{"nameIdentifier":"490949","nameIdentifierScheme":"WEKO"}]},{"creatorNames":[{"creatorName":"Okimoto, Tamaki"}],"nameIdentifiers":[{"nameIdentifier":"490950","nameIdentifierScheme":"WEKO"}]},{"creatorNames":[{"creatorName":"Ohno, Tatsuya"}],"nameIdentifiers":[{"nameIdentifier":"490951","nameIdentifierScheme":"WEKO"}]},{"creatorNames":[{"creatorName":"Tsuji, Hiroshi"}],"nameIdentifiers":[{"nameIdentifier":"490952","nameIdentifierScheme":"WEKO"}]},{"creatorNames":[{"creatorName":"Nakano, Takashi"}],"nameIdentifiers":[{"nameIdentifier":"490953","nameIdentifierScheme":"WEKO"}]},{"creatorNames":[{"creatorName":"Kamada, Tadashi"}],"nameIdentifiers":[{"nameIdentifier":"490954","nameIdentifierScheme":"WEKO"}]},{"creatorNames":[{"creatorName":"軽部 雅崇","creatorNameLang":"en"}],"nameIdentifiers":[{"nameIdentifier":"490955","nameIdentifierScheme":"WEKO"}]},{"creatorNames":[{"creatorName":"山本 直敬","creatorNameLang":"en"}],"nameIdentifiers":[{"nameIdentifier":"490956","nameIdentifierScheme":"WEKO"}]},{"creatorNames":[{"creatorName":"辻 比呂志","creatorNameLang":"en"}],"nameIdentifiers":[{"nameIdentifier":"490957","nameIdentifierScheme":"WEKO"}]},{"creatorNames":[{"creatorName":"鎌田 正","creatorNameLang":"en"}],"nameIdentifiers":[{"nameIdentifier":"490958","nameIdentifierScheme":"WEKO"}]}]},"item_language":{"attribute_name":"言語","attribute_value_mlt":[{"subitem_language":"eng"}]},"item_resource_type":{"attribute_name":"資源タイプ","attribute_value_mlt":[{"resourcetype":"journal article","resourceuri":"http://purl.org/coar/resource_type/c_6501"}]},"item_title":"Carbon-ion radiotherapy for patients with advanced stage non-small-cell lung cancer at multicenters","item_titles":{"attribute_name":"タイトル","attribute_value_mlt":[{"subitem_title":"Carbon-ion radiotherapy for patients with advanced stage non-small-cell lung cancer at multicenters"}]},"item_type_id":"8","owner":"1","path":["1"],"pubdate":{"attribute_name":"公開日","attribute_value":"2018-04-20"},"publish_date":"2018-04-20","publish_status":"0","recid":"48765","relation_version_is_last":true,"title":["Carbon-ion radiotherapy for patients with advanced stage non-small-cell lung cancer at multicenters"],"weko_creator_id":"1","weko_shared_id":-1},"updated":"2023-05-15T23:24:31.788374+00:00"}